IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Inogen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Inogen, Inc. (Inogen or the Company) (NASDAQ: INGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between November 8, 2017 and February 26, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before May 6, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

According to the Complaint, the Company made false and misleading statements to the market. Inogen overstated the total addressable market (TAM) for its portable oxygen concentrators, while also misstating the basis for its TAM calculations. The Company claimed that sales growth was based on an effective salesforce, when the growth was actually based on deceptive tactics used on an elderly client base. The Companys domestic growth was inflated and eroding other areas of its business. In fact, very little of Inogens sales were from the more stable Medicare market. Based on these facts, the Companys public statements were false and materially misleading throughout the class period. When the market learned the truth about Inogen, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm
Brian Schall, Esq.,
Sherin Mahdavian, Esq.,
www.schallfirm.com
Office:
310-301-3335
Cell: 424-303-1964
[email protected]